US life sciences firm LabCorp and its subsidiary Tapestri will partner with cell sequencer Mission Bio to improve identification of residual cancer cells. The collaboration will assess Mission Bio's Tapestri DNA sequencing platform, which can find individual cancer cells driving the disease, in the development of companion diagnostics that could improve patient care. LabCorp was among the investors in Mission Bio's $30m series B round last December.
US life sciences firm LabCorp and its subsidiary Covance will partner with cell sequencer Mission Bio to improve identification of residual cancer cells. The collaboration will assess Mission Bio's Tapestri DNA sequencing platform, which can find individual cancer cells driving the disease, in the development of companion diagnostics that could improve patient care. LabCorp was among the investors in Mission Bio's $30m series B round last December.